Eledon Pharmaceuticals Inc Overview
Industry: Biotechnology
Sector: Healthcare
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes Tegoprubart, an anti-CD40L antibody with high affinity for CD40 ligand, which is in Phase 2 clinical trial for kidney transplantation, IgA nephropathy, and amyotrophic lateral sclerosis, as well as preclinical Phase for xenotransplantation. The company is also developing AT-2001, which is preclinical Phase for autoimmune indications. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes Tegoprubart, an anti-C Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Eledon Pharmaceuticals Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Net loss was -$39M. Cash was $111.1M.
Net loss
-$39M
reported
Cash
$111.1M
reported
What changed
- Review the SEC source filing for the full reported results and management commentary.
Guidance / outlook
we expect multiple catalysts in 2026, including regulatory engagements supporting the advancement of tegoprubart into Phase 3 development in kidney transplantation and discussions regarding potential paths to market in islet cell transplantation.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
May 13, 2026
SEC filing
8-K
May 13, 2026
Earnings release
Earnings release
Mar 19, 2026
SEC filing
10-K
Mar 19, 2026
SEC filing
8-K
Mar 19, 2026
Earnings release
Earnings release
Nov 14, 2025
SEC filing
10-Q
Nov 14, 2025
SEC filing
8-K
Nov 14, 2025
SEC filing
8-K
Nov 07, 2025
Earnings material
Earnings release
Nov 07, 2025
SEC filing
10-Q
Aug 14, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Eledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw
Headline from Investing.com: Eledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw.
Earnings Per Share
Score 4.00/5
Eledon Pharmaceuticals Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 0.72/5
Eledon Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 2.21/5
Eledon Pharmaceuticals Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 3.80/5
Eledon Pharmaceuticals Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios